GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorAlbanell, J.
dc.contributor.authorMartinez, M. T. M.
dc.contributor.authorRamos, M.
dc.contributor.authorO'Connor, M.
dc.contributor.authorDe la Cruz-Merino, L.
dc.contributor.authorSantaballa Bertran, A.
dc.contributor.authorMartinez-Janez, N.
dc.contributor.authorMoreno, F.
dc.contributor.authorFernandez Perez, I.
dc.contributor.authorAlarcon Company, J.
dc.contributor.authorVirizuela Echaburu, J. A.
dc.contributor.authorDe la Haba Rodriguez, J.
dc.contributor.authorSanchez-Rovira, P.
dc.contributor.authorGonzalez-Cortijo, L.
dc.contributor.authorMargeli Vila, M.
dc.contributor.authorSanchez Munoz, A.
dc.contributor.authorGarau Llinas, I.
dc.contributor.authorCasas, M.
dc.contributor.authorBezares Montes, S.
dc.contributor.authorRojo Todo, F.
dc.contributor.authoraffiliation[Albanell, J.] GEICAM Spanish Breast Canc Grp, IMIM Hosp del Mar Med Res Inst, Hosp del Mar, CIBERONC ISCIII,Med Oncol Dept,Canc Res Program, Barcelona, Spain
dc.contributor.authoraffiliation[Martinez, M. T. M.] GEICAM Spanish Breast Canc Grp, Oncol, Ctr Oncol Galicia, La Coruna, Spain
dc.contributor.authoraffiliation[Ramos, M.] GEICAM Spanish Breast Canc Grp, Oncol, Ctr Oncol Galicia, La Coruna, Spain
dc.contributor.authoraffiliation[O'Connor, M.] Univ Hosp Waterford, Oncol, Canc Trials Ireland, Waterford, Ireland
dc.contributor.authoraffiliation[De la Cruz-Merino, L.] GEICAM Spanish Breast Canc Grp, Oncol, Hosp Virgen de la Macarena 7, Seville, Spain
dc.contributor.authoraffiliation[Santaballa Bertran, A.] GEICAM Spanish Breast Canc Grp, Hosp Univ & Politecn Fe, Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Martinez-Janez, N.] Hosp Univ Ramon y Cajal, GEICAM Spanish Breast Canc Grp, Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Moreno, F.] Hosp Clin Univ San Carlos, GEICAM Spanish Breast Canc Grp, Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Fernandez Perez, I.] Complejo Hosp Vigo Hosp Alvaro Cunqueiro, GEICAM Spanish Breast Canc Grp, Oncol, Vigo, Spain
dc.contributor.authoraffiliation[Alarcon Company, J.] GEICAM Spanish Breast Canc Grp, Hosp Son Espases, Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Virizuela Echaburu, J. A.] SEOM Soc Espanola Oncol Med, GEICAM Spanish Breast Canc Grp, Hosp Quiron Sagrado Corazon, Oncol, Seville, Spain
dc.contributor.authoraffiliation[De la Haba Rodriguez, J.] GECAM Spanish Breast Canc Grp, Ctr Invest Biomed Red Oncol, Hosp Reina Sofia, CIBERONC ISCIII,Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Sanchez-Rovira, P.] GEICAM Spanish Breast Canc Grp, Complejo Hosp Jaen, Oncol, Jaen, Spain
dc.contributor.authoraffiliation[Gonzalez-Cortijo, L.] Hosp Univ Quirosalud, GEICAM Spanish Breast Canc Grp, Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Margeli Vila, M.] Hosp Badalona Germans Trias & Pujol, GEICAM Spanish Breast Canc Grp, B ARGO Grp, Oncol,Catalan Inst Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Sanchez Munoz, A.] Hosp Univ Virgen de la Victoria, GEICAM Spanish Breast Canc Grp, Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Garau Llinas, I.] GEICAM Spanish Breast Canc Grp, Hosp Son Llatzer, Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Casas, M.] GEICAM Spanish Breast Canc Grp, Dept Stat, San Sebastian De Reyes, Spain
dc.contributor.authoraffiliation[Bezares Montes, S.] GEICAM Spanish Breast Canc Grp, Sci, Madrid, Spain
dc.contributor.authoraffiliation[Rojo Todo, F.] GEICAM Spanish Breast Canc Grp, Hosp Univ Fdn Jimenez Diaz, Oncol, Ctr Invest Biomed Red Oncol,CIBERONC ISCIII, Madrid, Spain
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T13:51:53Z
dc.date.available2025-01-07T13:51:53Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2247
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420423294/pdf
dc.identifier.urihttps://hdl.handle.net/10668/25918
dc.identifier.wosID573469102645
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationSAS - Hospital Universitario de Jaén
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS1151-S1151
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleGEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía
SAS - Hospital Universitario de Jaén
SAS - Hospital Universitario Virgen de la Victoria
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía